This provides greater applicability of the findings to general clinical practice, offering more useful information for physicians in their decision-making and providing a more realistic framework for the effectiveness of ultralow PSA in monitoring prostate cancer recurrence. The gene discussed is KLK3; the disease is prostate cancer.